Stockreport
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why [Yahoo! Finance]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Sciences GILD to develop and commercialize XLO's investigational oncology candidate, XTX301. XTX301 is Xilio's tumor-activated IL-12, developed using the company's proprietary tumor-activation platform, which is expected to have potential therapeutic benefit, both as a monotherapy and in combination therapy to treat a variety of solid tumors. XTX301 is currently being evaluated in a phase I dose-escalation study in patients with advanced solid tumors. The licensing agreement seeks to leverage Gilead Sciences' deep expertise in developing and commercializing novel immuno-oncology products to accelerate the development timeline of XTX301. On the other hand, the addition of XTX301 to GILD's pipeline of difficult-to-treat cancer therapies is expected to expand its immuno-oncology portfolio. Year to date, shares of Xilio have skyrocketed 121.8% against the industry's 7.9% decline. Image Source: Zacks Investment Research Per the terms of the agreement, upfront payments payable b
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy[Business Wire]
- ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder [Yahoo! Finance][Yahoo! Finance]
- One stock is dragging down the S&P 500's earnings growth [Yahoo! Finance Canada][Yahoo! Finance Canada]
- One stock is dragging down the S&P 500's earnings growth [Yahoo! Finance][Yahoo! Finance]
- Leap Therapeutics Reports First Quarter 2024 Financial Results [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- GILD's page on the SEC website
- More